Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Psychiatry
Volume 2014, Article ID 489493, 8 pages
http://dx.doi.org/10.1155/2014/489493
Case Report

QT Interval Prolongation Associated with Intramuscular Ziprasidone in Chinese Patients: A Case Report and a Comprehensive Literature Review with Meta-Analysis

1Beijing Key Laboratory of Mental Disorders, Department of Psychiatry, Beijing Anding Hospital, Capital Medical University, No. 5 Ankang Lane, Dewai Avenue, Xicheng District, Beijing 100088, China
2Center of Schizophrenia, Beijing Institute for Brain Disorders, Laboratory of Brain Disorders (Capital Medical University), Ministry of Science and Technology, Beijing 100088, China
3Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA 30322, USA
4Mental Health Research Center, Eastern State Hospital, University of Kentucky, Lexington, KY 40511, USA
5Psychiatry and Neurosciences Research Group (CTS-549), Institute of Neurosciences, University of Granada, 18071 Granada, Spain
6Biomedical Research Centre in Mental Health Net (CIBERSAM), Santiago Apóstol Hospital, University of the Basque Country, 01004 Vitoria, Spain

Received 31 May 2014; Revised 2 August 2014; Accepted 27 August 2014; Published 4 November 2014

Academic Editor: Alexander McGirr

Copyright © 2014 Xian-Bin Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Brook, J. Walden, I. Benattia, C. O. Siu, and S. J. Romano, “Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study,” Psychopharmacology, vol. 178, no. 4, pp. 514–523, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. J. C. Witsil, M. Zell-Kanter, and M. B. Mycyk, “Single-dose ziprasidone associated with QT interval prolongation,” The American Journal of Emergency Medicine, vol. 30, no. 5, pp. 837.e1–837.e2, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. A. H. Glassman and J. T. J. Bigger, “Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death,” The American Journal of Psychiatry, vol. 158, no. 11, pp. 1774–1782, 2001. View at Publisher · View at Google Scholar · View at Scopus
  4. R. Tambyraja and J. R. Strawn, “Third degree heart block following intramuscular ziprasidone,” Schizophrenia Research, vol. 125, no. 2-3, pp. 302–303, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. P. E. Keck Jr., M. Versiani, S. Potkin, S. A. West, E. Giller, and K. Ice, “Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial,” The American Journal of Psychiatry, vol. 160, no. 4, pp. 741–748, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. E. Poluzzi, E. Raschi, A. Koci et al., “Antipsychotics and torsadogenic risk: signals emerging from the US FDA adverse event reporting system database,” Drug Safety, vol. 36, no. 6, pp. 467–479, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. H. Zhang, G. Wang, J. Zhao et al., “Intramuscular ziprasidone versus haloperidol for managing agitation in chinese patients with schizophrenia,” Journal of Clinical Psychopharmacology, vol. 33, no. 2, pp. 178–185, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. R. M. Gallagher, J. J. Kirkham, J. R. Mason et al., “Development and inter-rater reliability of the Liverpool adverse drug reaction causality assessment tool,” PLoS One, vol. 6, no. 12, Article ID e28096, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Brook, J. V. Lucey, and K. P. Gunn, “Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis,” Journal of Clinical Psychiatry, vol. 61, no. 12, pp. 933–941, 2000. View at Publisher · View at Google Scholar · View at Scopus
  10. G. Chen, F. Deng, D. Wang, and K. Xu, “A control study of ziprasidone injection in treating schizophrenia during acute phase,” Journal of Anhui Medical & Pharmaceutical, vol. 14, pp. 1072–1073, 2010. View at Google Scholar
  11. D. G. Daniel, S. G. Potkin, K. R. Reeves, R. H. Swift, and E. P. Harrigan, “Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial,” Psychopharmacology, vol. 155, no. 2, pp. 128–134, 2001. View at Publisher · View at Google Scholar · View at Scopus
  12. D. G. Daniel, D. L. Zimbroff, R. H. Swift, and E. P. Harrigan, “The tolerability of intramuscular ziprasidone and haloperidol treatment and the transition to oral therapy,” International Clinical Psychopharmacology, vol. 19, no. 1, pp. 9–15, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Emul, M. Dalkiran, O. Coskun et al., “P wave and QT changes among inpatients with schizophrenia after parenteral ziprasidone administration,” Pharmacological Research, vol. 60, no. 5, pp. 369–372, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. X. Jiang, K. Yang, B. Zhou, C. Zhang, X. Gao, and X. Qian, “A clinical study of intramuscular ziprasidone in treating acute agitation in schizophrenia,” Shanghai Archives of Psychiatry, vol. 20, pp. 234–236, 2008. View at Google Scholar
  15. M. D. Lesem, J. M. Zajecka, R. H. Swift, K. R. Reeves, and E. P. Harrigan, “Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients,” The Journal of Clinical Psychiatry, vol. 62, no. 1, pp. 12–18, 2001. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Li, Y. Zhou, Q. Ji, and L. Jiang, “Comparative study of ziprasidone versus haloperidol injection in the treatment of schizophrenia in acute phase,” Shanghai Archives of Psychiatry, vol. 22, pp. 233–235, 2010. View at Google Scholar
  17. A. Mautone and S. Scarone, “Transition from ziprasidone im to oral formulation in agitated patients with acute exacerbation of schizophrenia: an open trial,” Pharmacopsychiatry, vol. 44, no. 5, pp. 173–178, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. J. J. Miceli, K. D. Wilner, S. K. Swan, and T. G. Tensfeldt, “Pharmacokinetics, safety, and tolerability of intramuscular ziprasidone in healthy volunteers,” Journal of Clinical Pharmacology, vol. 45, no. 6, pp. 620–630, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. J. J. Miceli, T. G. Tensfeldt, T. Shiovitz, R. J. Anziano, C. O'Gorman, and R. H. Harrigan, “Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: A randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder,” Clinical Therapeutics, vol. 32, no. 3, pp. 472–491, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. H. Preval, S. G. Klotz, R. Southard, and A. Francis, “Rapid-acting IM ziprasidone in a psychiatric emergency service: a naturalistic study,” General Hospital Psychiatry, vol. 27, no. 2, pp. 140–144, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. A. R. Rais, K. Williams, T. Rais, T. Singh, and M. Tamburrino, “Use of intramuscular ziprasidone for the control of acute psychosis or agitation in an inpatient geriatric population: an open-label study,” Psychiatry, vol. 7, no. 1, pp. 17–24, 2010. View at Google Scholar · View at Scopus
  22. X. Yin and G. Wang, “A study of intramuscular ziprasidone and haloperidol in treating acute agitation in schizophrenia,” Chinese Modern Medicine, vol. 19, pp. 9–11, 2012. View at Google Scholar
  23. C. J. Dunst and D. W. Hamby, “Guide for calculating and interpreting effect sizes and confidence intervals in intellectual and developmental disability research studies,” Journal of Intellectual and Developmental Disability, vol. 37, no. 2, pp. 89–99, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. K. Ried, “Interpreting and understanding meta-analysis graphs: a practical guide,” Australian Family Physician, vol. 35, no. 8, pp. 635–638, 2006. View at Google Scholar · View at Scopus
  25. J. Wang, X. Xu, Y. Ou, and W. Li, “The second phase clinical trials of intramuscular Ziprasidone for the treatment of acute psychotic agitation of the schizophrenia,” Nervous Diseases and Mental Health, vol. 7, pp. 364–370, 2008. View at Google Scholar
  26. H. Sanaei-Zadeh, “QT interval—what is normal? Comment on “single-dose ziprasidone associated with QT interval prolongation”,” The American Journal of Emergency Medicine, vol. 30, no. 4, p. 627, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. L. E. Friberg, G. K. Isbister, and S. B. Duffull, “Pharmacokinetic-pharmacodynamic modelling of QT interval prolongation following citalopram overdoses,” British Journal of Clinical Pharmacology, vol. 61, no. 2, pp. 177–190, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. N. Fleeman, Y. Dundar, R. Dickson et al., “Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses,” Pharmacogenomics Journal, vol. 11, no. 1, pp. 1–14, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. S. G. Priori, P. J. Schwartz, C. Napolitano et al., “Risk stratification in the long-QT syndrome,” New England Journal of Medicine, vol. 348, no. 19, pp. 1866–1874, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. E. Spina and J. de Leon, “Clinically relevant interactions between newer antidepressants and second-generation antipsychotics,” Expert Opinion on Drug Metabolism & Toxicology, vol. 10, no. 5, pp. 721–746, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. A. J. Camm, O. N. Karayal, H. Meltzer et al., “Ziprasidone and the corrected QT interval: a comprehensive summary of clinical data,” CNS Drugs, vol. 26, no. 4, pp. 351–365, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. Bedfor laboratories, “Haloperidol-haloperidol lactate injections. Prescribing information,” Bedford laboratories, Bedfor, Ohio, USA, 2011, http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4863db55-cf54-4ec3-96c7-e534a3aa8eeb.